The NZ Drug Foundation's analysis zooms into key questions such as changes in the domestic legal framework, impact on social equity and harm reduction.
The Forum provided a space for UN, state and civil society representatives to consider how best to progress health, human rights and development in relation to drug policies.
The American Medical Association calls for increased access to healthcare and harm reduction efforts as part of a response to the growing overdose death rates in the United States.
Shaleen Title lays out a set of policy proposals to promote the growth of a diverse and competitive market, centring consumers and public health while building on effective equity programs already at work in state markets.
Handanagic et al. provide updated prevalence estimates of HIV infection and behaviours associated with HIV infection since the last NHBS survey among people who inject drugs in 2015, and represents a snapshot of the HIV prevention landscape for people who inject drugs before the COVID-19 pandemic.
Gabri et al. conclude that changes in cannabis legislation do not have an impact on the prevalence of recreational cannabis use among youth and young adults in Europe.
Chiedozie Arum et. al. conclude that homelessness and unstable housing are associated with increased risk of HIV and HCV acquisition among people who inject drugs.
IDPC releases a user-friendly resource for people from all sectors who wish to understand the key objectives, principles and concepts relating to decriminalisation of drug use and how to advocate for it.
Collaborating under the Support. Don't Punish campaign, IDPC & ARASA provide an overview of the key questions that drug decriminalisation advocates should consider to demand reform.
